ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

GPCR vs ETON // EV/EBITDA & P/E VALUATION

Structure Therapeutics Inc. (NASDAQ) VS. Eton Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: GPCR 1 — ETON 4
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (GPCR VS. ETON) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC GPCR ETON SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 53.50% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -19.50% -0.90% -18.60 ETON /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — — — TIE /valuation <GO>
Free Cash Flow Yield -14.43% 0.66% -15.09 ETON /fcf-yield <GO>
Operating Margin — -1.10% — TIE /operating-margins <GO>
Net Profit Margin — -5.80% — TIE /net-margins <GO>
Revenue Growth (YoY) — 104.90% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 13.37 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 1/9 7/9 -6.00 ETON /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 26.5 47.9 -21.37 ETON /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $1.56B $1.53B $30.5M GPCR /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR GPCR REV ETON REV GPCR GROSS % ETON GROSS % GPCR FCF ETON FCF
FY 2025 $0 $80.0M — 53.5% -$225.8M $10.2M
FY 2024 $0 $39.0M — 60.0% -$117.9M $943.0K
FY 2023 $0 $31.6M — — -$79.5M $6.8M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
GPCR // BETA —
ETON // BETA —